Pharmaceutical Technology
October 02, 2010
From The Editor
34
10
The reopened debate over embryonic-stem-cell research could stifle many other scientific pursuits.
October 02, 2010
Peer-Reviewed
34
10
The authors describe a technique designed to yield low-density powders with a tailored particle-size distribution over a broad range of respiratory flow rates.
October 02, 2010
Ingredients Insider
34
10
A recently released industry guide outlines a science- and risk-based approach to control the risk of cross-contamination.
October 02, 2010
Special Report
34
10
The growth of biologics is an important factor for the injectable-drug delivery systems market. A look at the technical and market considerations affecting this sector.
October 02, 2010
PharmTech Talk
34
10
Private companies and universities are developing new ways to deliver protein drugs.
October 02, 2010
News
34
10
Public-private R&D partnerships are on the rise across Europe, but national goals and academia-industry competition could prevent their success at the European level.
October 02, 2010
Outsourcing Outlook
34
10
Global pharmaceutical companies could have a problem getting rid of redundant facilities.
October 02, 2010
In the Spotlight
34
10
Editors' picks of pharmaceutical science and technology innovations.
October 02, 2010
Online Exclusives
34
10
An expert-panel-written book has surprising shortcomings.
October 02, 2010
Special Report
34
10
Drugmakers hatch new manufacturing paradigms in the wake of the 2009 H1N1 influenza pandemic.
October 02, 2010
Online Exclusives
34
10
The authors provide a brief overview of the European pharmaceutical regulation with regard to batch certification by a qualified person and batch release for the European market.
October 02, 2010
Agent-in Place
34
10
From disagreement to denial, being cordial about quality control can be challenging.
October 02, 2010
Online Exclusives
34
10
Pfizer's acquisition of Wyeth involves augmenting its biopharmaceutical product portfolio, pipeline, and related development and manufacturing capabilities.
October 02, 2010
Industry Leaders
34
10
The president of Gibraltar Laboratories, Daniel Prince, discusses industry trends and challenges.
October 02, 2010
News
34
10
A look at MVI's malaria work in developing countries.
October 02, 2010
Online Exclusives
34
10
Novartis' Matthew Stober discusses vaccine manufacturing, including egg- and cell-based systems.
October 02, 2010
Viewpoint
34
10
In light of compendial changes, representatives of the US Pharmacopeia and an industry consortium provide perspectives on cap and ferrule labels.
October 02, 2010
Peer-Reviewed
34
10
The authors developed a formulation for effervescent gastroretentive drug delivery techniques using ibuprofen as a model drug. They optimized the formulations by applying full factorial design.
October 02, 2010
Washington Report
34
10
President Obama and HHS eye innovation and countermeasures to protect public health.
October 02, 2010
Inside EDQM
34
10
The EDQM inspection program helps to ensure the quality of APIs on the European market.
October 01, 2010
Issue PDF
34
10
Vaccine Manufacturing Reborn